Targeting imipramine dose in children with depression.

Area of Science:

• Pharmacology
• Child Psychiatry
• Clinical Pharmacy

Background:

• Imipramine (IMI) response in depressed children correlates with total IMI and desmethylimipramine (DMI) levels.
• Understanding pharmacokinetics is crucial for effective pediatric depression treatment.

Purpose of the Study:

• To examine the pharmacokinetics of IMI + DMI in children with depression.
• To propose a single-point prediction method for steady-state IMI + DMI levels.
• To determine feasibility of achieving minimum therapeutic concentrations for prepubertal depression.

Main Methods:

• Administered a single 25 mg oral dose of IMI to children with depression.
• Measured plasma concentrations of IMI + DMI 24 hours post-dosing.
• Correlated single-point measurements with steady-state levels in children receiving 3 mg/kg/day IMI.

Main Results:

• A strong correlation (r = 0.92) was found between single-point plasma IMI + DMI levels and steady-state levels.
• The 24-hour post-dose concentration accurately predicted therapeutic levels.
• The method demonstrated feasibility and reliability within theoretical limits.

Conclusions:

• A single 25 mg IMI dose allows for reliable prediction of steady-state IMI + DMI levels in pediatric depression.
• This approach enables precise IMI dosing to rapidly achieve minimum therapeutic concentrations.
• The findings support a feasible and reliable strategy for optimizing imipramine treatment in children.